Abstract
BackgroundSubgroup analyses of randomized trials suggest the superiority of immune checkpoint inhibitor-based therapy over chemotherapy in patients with mismatch-repair deficient (dMMR) and/or microsatellite instability-high (MSI-high) advanced gastric or gastroesophageal junction...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have